R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond

Antiviral Res. 2008 Jun;78(3):278-81. doi: 10.1016/j.antiviral.2008.01.002. Epub 2008 Feb 4.

Abstract

In this study the antiviral activity of a panel of 18 out of 240 pyridazinamine analogues was evaluated against the Sabin strains of the three poliovirus types. We found one compound, R75761 which had a comparable 50% effective concentration (EC50) value against all three poliovirus Sabin strains. Virus multiplication was reduced by 10(4.0)-fold, 10(6.2)-fold and 10(6.6)-fold for poliovirus type 1, type 2 and type 3, respectively. R75761 could be considered as a lead compound for development of anti-poliovirus drugs to be used during the late stage of poliovirus eradication and beyond.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiviral Agents / pharmacology*
  • Cytopathogenic Effect, Viral / drug effects
  • HeLa Cells
  • Humans
  • Poliomyelitis / drug therapy
  • Poliomyelitis / prevention & control*
  • Poliomyelitis / virology
  • Poliovirus / classification
  • Poliovirus / drug effects*
  • Poliovirus / physiology
  • Poliovirus Vaccine, Oral*
  • Pyridazines / chemistry
  • Pyridazines / pharmacology*
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • Poliovirus Vaccine, Oral
  • Pyridazines